Details
Stereochemistry | ACHIRAL |
Molecular Formula | C24H30N4O |
Molecular Weight | 390.5212 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CCN(CC)CCCNC(=O)CN1N=CC(=C1C2=CC=CC=C2)C3=CC=CC=C3
InChI
InChIKey=PRHCHMGCDBUACR-UHFFFAOYSA-N
InChI=1S/C24H30N4O/c1-3-27(4-2)17-11-16-25-23(29)19-28-24(21-14-9-6-10-15-21)22(18-26-28)20-12-7-5-8-13-20/h5-10,12-15,18H,3-4,11,16-17,19H2,1-2H3,(H,25,29)
Ipazilide is an antiarrhythmic agent that prolongs ventricular refractoriness and possesses antiectopic activity. In clinical trials ipazilide administrations leads to dose- and time-dependent in decrease cardiac index and arterial pressure. Left ventricular filling pressure, right atrial pressure, and heart rate were not altered by ipazilide. Plasma concentrations of ipazilide peaked 90 minutes after administration of 100 or 200 of the drug, but peak concentrations were noted 3 hours after administration of 400 mg. The hemodynamic response correlated with the plasma concentration of ipazilide determined contemporaneously.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: Potassium channel Sources: https://adisinsight.springer.com/drugs/800001765 |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/8033497
400, 200, and 100 mg single-dose
Route of Administration:
Oral
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C47793
Created by
admin on Fri Dec 15 17:19:57 GMT 2023 , Edited by admin on Fri Dec 15 17:19:57 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
CHEMBL2111169
Created by
admin on Fri Dec 15 17:19:57 GMT 2023 , Edited by admin on Fri Dec 15 17:19:57 GMT 2023
|
PRIMARY | |||
|
C83832
Created by
admin on Fri Dec 15 17:19:57 GMT 2023 , Edited by admin on Fri Dec 15 17:19:57 GMT 2023
|
PRIMARY | |||
|
WDN6V96D5U
Created by
admin on Fri Dec 15 17:19:57 GMT 2023 , Edited by admin on Fri Dec 15 17:19:57 GMT 2023
|
PRIMARY | |||
|
SUB08270MIG
Created by
admin on Fri Dec 15 17:19:57 GMT 2023 , Edited by admin on Fri Dec 15 17:19:57 GMT 2023
|
PRIMARY | |||
|
100000083119
Created by
admin on Fri Dec 15 17:19:57 GMT 2023 , Edited by admin on Fri Dec 15 17:19:57 GMT 2023
|
PRIMARY | |||
|
DTXSID2043799
Created by
admin on Fri Dec 15 17:19:57 GMT 2023 , Edited by admin on Fri Dec 15 17:19:57 GMT 2023
|
PRIMARY | |||
|
115436-73-2
Created by
admin on Fri Dec 15 17:19:57 GMT 2023 , Edited by admin on Fri Dec 15 17:19:57 GMT 2023
|
PRIMARY | |||
|
6567
Created by
admin on Fri Dec 15 17:19:57 GMT 2023 , Edited by admin on Fri Dec 15 17:19:57 GMT 2023
|
PRIMARY | |||
|
60650
Created by
admin on Fri Dec 15 17:19:57 GMT 2023 , Edited by admin on Fri Dec 15 17:19:57 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
SALT/SOLVATE (PARENT)